-
EOFlow Officially Launches iOS Version of the EOPatch App ‘Narsha’
▶ iOS version of the world’s first app for controlling wearable insulin pump ▶ Improved ease of use by replacing a portable controller with a smartphone app EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announces that it officially launches iOS Version of ‘Narsha,’ a smartphone application for wearable insulin pump in Korea. It has been nine months since the Company officially launched the Android application of Narsha. Narsha is the world’s first...May. 17. 2022 -
EOFlow Announces Record Revenue for First Quarter 2022; Revenue of 949 Million KRW which is 137% of Last Year’s Annual Revenue
▶ Highest-ever quarterly revenue! Strong revenue growth from European sales; Menarini will progressively launch the product in Europe from 2Q22 onwards! ▶ EOFlow expects significant growth in revenue in 2022 from market launches in Europe, Indonesia, and the Middle East EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced its Q1 financial results ended on March 31, 2022. EOFlow announced its consolidated financial results: first quarter of 2022 revenue of 949 million Korean...May. 16. 2022 -
EOFlow Has its First Clinical Study on EOPatch Published in Diabetes & Metabolism Journal
▶ A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus ▶ 4-week treatment with EOPatch was safe and led to clinically meaningful improvement in glycemic control compared to those with MDI or conventional insulin pump EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that its first clinical study results on the wearable insulin pump EOPatch in patients with type 1 diabetes were publ...Apr. 11. 2022 -
EOFlow to Supply KRW48.8bn Worth of EOPatch to Gulf Drug of UAE
▶ A Major Export Deal for EOFlow’s Innovative Insulin Pump EOPatch EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced on March 31 that it has signed a contract with GulfDrug LLC (Gulf Drug) of the United Arab Emirates (UAE) to supply 48.8 billion Korean won (40 million US dollar) worth of EOPatch, a disposable and wearable insulin pump, over the course of five years. The Company said the contract amount is equivalent to 7043 percent (%) of its entire sales last year. T...Apr. 04. 2022 -
EOFlow announces two clinical study plans supported by Korean government
EOFlow has announced that the company will conduct two clinical studies in 2021, both supported by Korean government research grants. One study will be aiming at Type 2 diabetic people using the current wearable disposable insulin pump, EOPatch. This study involves four university-hospitals and up to 120 Type 2 diabetic patients. The other study will be aiming at Type 1 diabetic people using EOFlow's first wearable closed-loop solution (automated insulin delivery), EOPatch X. This study has 6 university-hospitals signed up and a...Dec. 14. 2020 -
EOFlow publishes the final report on its first clinical trial
On December 3, 2020, EOFlow announces that it has received the final report on the post-market clinical study on EOPatch wearable insulin pump system, conducted in Korea over the summer this year. The study was conducted on 9 patients over a month's time and it showed significant improvement on TIR (Time in Range), with subject patients staying within the target blood glucose range (70~180mg/dL) much longer, and having significantly less incidents of severe hypoglycemic events (<54mg/dL). 7 patients out of 9 had expressed the...Dec. 09. 2020 -
EOFlow goes IPO
EOFlow just went public in Korea on September 14, 2020. The company is listed on KOSDAQ market, with the identification number (equivalent to ticker symbol) of 294090. Hana Financial Investment was the underwriter for the company. The company offered 1.4M shares at the initial price of 19,000 KRW per share.Sep. 16. 2020 -
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner October 10th, 2019, Bangkok, Thailand — Today, Red Herring announced its Top 100 Asia award winners in recognition of the leading private companies from the region, celebrating these startups’ innovations and technologies across their respective industries. Red Herring Top 100 Asia enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1000 privately financed companies each year in the Asia. Since 1996, ...Oct. 15. 2019 -
EOFLOW Chosen as Company of the Year
EOFLOW made it to the 'Top 10 Diabetes Care Solutions Providers - 2019' list and was chosen as the Company of the Year by Medtech Outlook magazine (see the attachment for a reprint). One can read more about it at: https://diabetes-care.medicaltechoutlook.com/vendors/top-diabetes-care-companies.htmlOct. 07. 2019 -
Menarini Diagnostics & EOFlow sign a long term business agreement
EOFlow Co., Ltd. and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of Innovative Insulin Patch Pump Seoul, South Korea and Florence, Italy 17 September 2019 – EOFlow Co., Ltd., developer of novel wearable drug delivery solutions, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the Insulin Patch Pump product developed by EOFlow Co., Ltd. “We are very pleased and excited to work with A. Menarini Diagno...Sep. 17. 2019 -
Improved EOPatch is approved in Korea
EOFlow announced yesterday that its improved EOPatch recently obtained a regulatory approval from the Korean MFDS (Ministry of Food and Drug Safety). The new EOPatch has a number of new features that improve users' experience, including the adoption of a soft cannula for more comfortable wear and extending the life of the Patch (wearable disposable pump unit) to 3.5days. This extension of half a day (previously 3days) will allow users a weekly routine of changing two Patches on the same days of the week, improving the overal...Jul. 10. 2019 -
EOFLOW Receives Breakthrough Device Designation from FDA
EOFlow Receives FDA Breakthrough Device Designation on its Integrated Wearable Automated Insulin Delivery System SAN JOSE, USA and SEOUL, South Korea, March 14, 2019 EOFLOW CO., Ltd., an emerging medical device company with offices in Seoul, South Korea and San Jose, California, announced today that its closed loop Automated Insulin Delivery /Artificial Pancreas Device (AID/AP), the EOPancreas System, has received Breakthrough Device Designation by the U.S. Food and Drug Administration. The EOPancreas System is designed to pr...Mar. 14. 2019 -
EOFLOW presents at Diabetes Technology Meeting
Dr. Ian Welsford, the Chief Compliance Officer at EOFLOW, spoke at the 2018 Diabetes Technology Meeting held in Bethesda, MD on November 8th. At the event, Dr. Welsford presented 'A Novel Patch Pump' where he discussed the possibilities of a smart wearable insulin patch pump.Nov. 15. 2018 -
EOFLOW awarded at Start-Up Festival 2018
EOFLOW was one of the top two award winners at the SF2018 (Start-up Festival 2018), a highly recognized event for startups, held by KISED (Korean Institute of Startups and Entrepreneurship Development) and sponsored by the Ministry of SMEs and Startups. EOFLOW is being recognized as one of the fastest growing and most successful startup companies in Korea.Nov. 09. 2018
Healthcare Innovation Park #H2202 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
